# Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

> clinical trial · VERIFIED · 2026-08-24

Status: SUSPENDED · Sponsor: Children's Oncology Group · Condition: Childhood Fibrolamellar Carcinoma

- Company: Children's Oncology Group
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06620302

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.